ISSN: 2161-0460
Journal of Alzheimers Disease & Parkinsonism
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

A Pleotrophic Age for Alzheimer and Parkinson disease

George Perry1*, Elizabeth A. Perry1, Xiongwei Zhu2 and Rudy Castellani3
1Department of Biology, University of Texas at San Antonio, San Antonio, Texas, USA
2Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA
3Department of Pathology, University of Maryland, Baltimore, Maryland, USA
Corresponding Author : George Perry, Ph.D
College of Sciences, University of Texas at San Antonio
One UTSA Circle, San Antonio, Texas 78249, USA
E-mail: george.perry@utsa.edu
Received March 26, 2012; Accepted March 27, 2012; Published March 29, 2012
Citation: Perry G, Perry EA, Zhu X, Castellani R (2012) A Pleotrophic Age for Alzheimer and Parkinson disease. J Alzheimers Dis 2:e109. doi: 10.4172/2161-0460.1000e109
Copyright: © 2012 Perry G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Alzheimers Disease & Parkinsonism

In an optimistic world, now is the most exciting of times in the study of Alzheimer and Parkinson diseases. Over the past century, the major genetic loci have been identified, the pathology has been described, and clinical and diagnostic criteria defined. Despite these facts, the stalemate in efforts to find effective therapeutics continues. Yet scientists remain hopeful that the next kernel of information will unlock a major breakthrough, even as decades of work by brilliant researchers has, for practical purposes, failed in this regard.
Noteworthy is that scientists are following models that were successful in resolving infectious and childhood diseases in the past century, but those same models have advanced us but little, if at all, in treating chronic disease. We appear to be collecting data on an intractable problem that requires insight beyond the amyloid cascade, oxidative stress, cholesterol, cell cycle, infectious, or any of the other theories put forward that explain only features of the disease.
In the case of Alzheimer’s disease, we are left with increasing confusion as to how to proceed except to redefine the clinical and biochemical basis to categorizations that are even more difficult to resolve; note the variation in the definition of oligomers and the continuous refinement of clinical and pathological features, both of which appear to have reached the point of diminishing returns.
Stepping aside from these diseases, the medical community has met similar roadblocks for most age-related chronic diseases where we at best provide therapeutics to alter the slope of decline rather than change the course of disease. Pessimism opens the opportunity for those who look beyond the specifics to understand the fundamental remodeling of aging that fails during disease. With the opening provided by the growing talent now working in this field, it is our hope that a similar opening of the field to integrative insights will follow.
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11254
  • [From(publication date):
    March-2012 - Sep 28, 2016]
  • Breakdown by view type
  • HTML page views : 7508
  • PDF downloads :3746
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version